< Terug naar vorige pagina
Onderzoeker
Peter Bossuyt
- Disciplines:Endocrinologie en metabole ziekten, Gastro-enterologie en hepatologie, Ontdekking en evaluatie van biomarkers, Ontdekking en evaluatie van geneesmiddelen, Medicinale producten, Farmaceutica, Farmacognosie en fytochemie, Farmacologie, Farmacotherapie, Toxicologie en toxinologie, Andere farmaceutische wetenschappen
Affiliaties
- Translationeel Onderzoek van Gastro-enterologische Aandoeningen (TARGID) (Afdeling)
Lid
Vanaf1 jun 2015 → Heden
Publicaties
1 - 10 van 151
- Autoimmune Pancreatitis in Patients with Inflammatory Bowel Disease: A Real-World Multicentre Collaborative ECCO CONFER Study(2023)
Auteurs: Bram Verstockt, Peter Bossuyt
Pagina's: 1791 - 1799 - Effect of 104 Weeks of Mirikizumab Treatment on Inflammatory Bowel Disease Questionnaire Scores Among Patients With Moderately to Severely Active Crohn's Disease(2023)
Auteurs: Peter Bossuyt
Pagina's: S809 - S809 - Mirikizumab Sustained Improvement on Fatigue in Patients With Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study at Week 104(2023)
Auteurs: Peter Bossuyt
Pagina's: S816 - S816 - Long-term follow-up of the red density pilot trial: a basis for long-term prediction of sustained clinical remission in ulcerative colitis?(2023)
Auteurs: Pieter Sinonquel, Peter Bossuyt, João Guedelha Sabino, Bram Verstockt, Séverine Vermeire, Raf Bisschops
Pagina's: E880 - E884 - Patient-reported Outcomes and Disability Are Associated with Histological Disease Activity in Patients with Ulcerative Colitis: Results from the APOLLO Study(2023)
Auteurs: Bram Verstockt, Peter Bossuyt
Pagina's: 1046 - 1054 - ECCO Topical Review on Biological Treatment Cycles in Crohn's Disease(2023)
Auteurs: Peter Bossuyt
Pagina's: 1031 - 1045 - DEVELOPMENT OF A BELGIAN CORE SET OF QUALITY OF CARE MEASUREMENTS FOR PATIENTS WITH INFLAMMATORY BOWEL THROUGH A NATIONAL DELPHI PROCESS(2023)
Auteurs: Peter Bossuyt, Caroline Weltens, Marc Ferrante
Pagina's: S676 - S677 - CHANGE IN FATIGUE IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE INITIATING VEDOLIZUMAB OR OTHER BIOLOGIC THERAPY: DATA FROM BELGIAN REGISTRY PATIENTS(2023)
Auteurs: Peter Bossuyt
Pagina's: S751 - S751 - INTERIM RESULTS FROM THE RANDOMIZED VERDICT TRIAL TO DETERMINE THE OPTIMAL TREATMENT TARGET IN PATIENTS WITH ULCERATIVE COLITIS(2023)
Auteurs: Peter Bossuyt
Pagina's: S1107 - S1108 - NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF INTRAVENOUS AND SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS(2023)
Auteurs: Peter Bossuyt
Pagina's: S654 - S654